

Serial No.: 10/664,601

RECEIVED  
CENTRAL FAX CENTER

SEP 21 2006

REMARKS

Claims 1-36 are pending in the application. Restriction is required to the following allegedly distinct inventions:

- I. Claims 1-29 and 33-36, drawn to a dosage form and method of forming said dosage form, classified, for example when the dosage form is an insertable or injectable chemical ablation agent with a biodisintegrable binder in class 424, subclass 9.2, 1.25, 1.33, 9.411, 422, 428, and 489;
- II. Claims 27-29, drawn to a method of forming the dosage, classified, for example when the dosage form is said ablation agent and said biodisintegrable binder in class 424, subclass 9.2;
- III. Claim 22-26 and 30-32, drawn to a method of treatment, classified, for example when a treatment comprised of inserting, injecting transcutaneously, or transrectally via jet injection in class 424, subclass 422 and 9.6.

Applicants elect the Group I claims, Claims 1-29 and 33-36, with traverse, for initial prosecution on the merits.

Pursuant to 35 U.S.C. 121, election of a single disclosed species for prosecution on the merits is also required. Applicants hereby elect Species I (dosage form), as the single disclosed species for prosecution on the merits. Claims 1-21 and 33-36 are readable thereon.

Serial No.: 10/664,601

Should the Examiner be of the view that an interview would expedite consideration of the application, request is made that the Examiner telephone the Applicants' attorney at (908) 518-7700 in order that any outstanding issues be resolved.

Respectfully submitted,



Keum J. Park  
Registration No. 42,059

I hereby certify that this correspondence is being deposited with the United States Patent and Trademark Office on 9/21/06 via facsimile to: 571-273-8300.

Marjorie Scariati  
(Printed Name of Person Mailing Correspondence)

  
(Signature)